72.11.Z - Research and experimental development on biotechnology
62.01.Z - Computer programming activities
62.02.Z - Computer consultancy activities
62.09.Z - Other information technology and computer service activities
72.19.Z - Other research and experimental development on natural sciences and engineering
2019 | 2020 | 2021 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0 | -0 | -0 | 91,5 |
EBITDA | -0 | -0 | -0 | 90,4 |
Short time liabilities | 0 | 0 | 0 | 92,4 |
Equity capital | 0,3 | 0,2 | 0,2 | -0,8 |
Operating profit (EBIT) | -0 | -0 | -0 | 90,4 |
Assets | 1 | 0,9 | 0,9 | 0 |
Net profit (loss) | -0 | -0 | -0 | 91,5 |
Cash | 0,3 | 0 | 0 | 0,7 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 0,7 | 0,7 | 0,7 | 0,3 |
Working assets | 0,8 | 0,8 | 0,8 | 6,9 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -9,6 | -9,7 | -0,8 | 8,9 |
Equity capital to total assets | 26,7 | 27,3 | 27 | -0,3 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 0 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 1.8854155540466309 | 1.2040303945541382 | 1.2784007787704468 | 0,1 |
Net dept to EBITDA | 0.2926955223083496 | 0.23459492623806 | 3.5689125061035156 | 3,4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane